At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Nov 12, 2026 at 10:28 ET
Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rate by 83% vs placebo (p<0.0001) across all HAE types, with 45% of patients attack-free over 24 weeks. The drug was generally well tolerated with no treatment-related serious adverse events. This is a late-stage biotech with a $2.4B market cap, and the data supports its potential as an oral prophylactic therapy for HAE.
- Phase 3 CHAPTER-3 met primary and all secondary efficacy endpoints with statistical significance
- Deucrictibant XR reduced monthly HAE attack rate by 83% vs placebo across all HAE types (p<0.0001)
- In HAE Type 1 or 2, attack rate reduced by 87% vs placebo
- 45% of deucrictibant-treated participants were attack-free over the entire 24-week treatment period
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access